YMAB - Y-mAbs Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
22.00
+2.52 (+12.94%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close19.48
Open19.63
Bid0.00 x 1200
Ask22.60 x 900
Day's Range18.00 - 22.49
52 Week Range18.00 - 31.00
Volume137,614
Avg. Volume276,680
Market Cap752.261M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.29
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est30.00
Trade prices are not sourced from all markets
  • GlobeNewswire23 days ago

    Y-mAbs Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the closing of its initial public offering of 6,900,000 shares of its common stock, including the exercise in full of the underwriters' option to purchase 900,000 additional shares of common stock, at a public offering price of $16.00 per share.  The gross proceeds to Y-mAbs, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $110.4 million.  All of the shares of common stock were offered by the Company.

  • MarketWatch28 days ago

    Y-mAbs' stock soars above IPO price in its public debut

    Shares of Y-mAbs Therapeutics Inc. soared in their public debut Friday, as they opened 66% above the initial public offering price of $16, and get rising. The first trade for the pediatric cancer biotech's stock was at $26.50 at 10:58 a.m. ET for 444,194 share. The stock was recently up 71% at $27.36, and has traded in a range of $26 to $28.03 since the open. The company sold 6 million shares to raise $96 mililon in the IPO, which is trading on the Nasdaq under the ticker symbol "YMAB." The stock went public at a time that the Renaissance IPO ETF has gained 0.6% over the past three months and the S&P 500 has advanced 6.7%.

  • MarketWatch28 days ago

    Pediatric cancer biotech Y-mAbs Therapeutics raises $96 million in IPO

    Pediatric cancer biotech Y-mAbs Therapeutics Inc. priced its initial public offering late Thursday at $16 a share, selling 6 million shares to raise $96 million. Shares will start trading later Friday on Nasdaq, under the ticker symbol "YMAB". BofA Merrill Lynch and Cowen were joint bookrunners on the deal with Canaccord Genuity acting as lead manager and BTIG acting as co-manager.

  • The Wall Street Journal28 days ago

    [$$] Y-mAbs Therapeutics Sells Extra Shares in IPO

    Y-mAbs Therapeutics Inc. said it sold 6 million shares for $16 each in its initial public offering, raising $96 million.

  • GlobeNewswire28 days ago

    Y-mAbs Therapeutics Announces Pricing of Initial Public Offering

    Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (YMAB) a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $96 million, before underwriting discounts and commissions and estimated offering expenses payable by the Company. All shares are being offered by the Company.